1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HLA associations with immunotherapy related endocrine toxicity
    Meeting Abstract

    Quandt, Z.; Thorball, C.; Middha, P.; Johnson, D. B.; Bejan, C. A.; Yao, L.; Xu, Y.; Hodel, F.; Stravodimou, A.; Shearer-Kang, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT
    Meeting Abstract

    Bejanyan, N.; Ho, V.; Perales, M. A.; Kebriaei, P.; Kaur, M.; Zhang, M. J.; D'Amico, P. G.; Purcell, S.; Dorman, S.; Vandendries, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes
    Meeting Abstract

    Zenner, M.; Lessans, S.; Rejeski, K.; Perales, M. A.; Maziarz, R. T.; Chen, A. I.; Porter, D. L.; Schuster, S. J.; McGuirk, J.; Bishop, M. R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors
    Meeting Abstract

    Spira, A. I.; Lee, E. K.; O'Cearbhaill, R. E.; LoRusso, P.; Falchook, G. S.; Patel, M. R.; Richardson, D. L.; Lu, W.; Marreddy, P.; Farrington, D. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Multi-institution real world analysis of patients with non-small cell lung cancer (NSCLC) treated with standard of care (SOC) neoadjuvant chemo-immunotherapy (chemoIO)
    Meeting Abstract

    Cooper, A. J.; Gorria, T.; Conroy, M. R.; Ricciuti, B.; Pecci, F.; Aldea, M.; Anagnostou, V.; Shaverdian, N.; Bott, M.; Forde, P. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)
    Meeting Abstract

    Lesokhin, A. M.; Raza, M. S.; Acosta, J.; Muller, P.; O'Connell, A.; Yver, A.; Lou, C.; Finn, G.; Service, M.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naive myelofibrosis and moderate thrombocytopenia
    Meeting Abstract

    Scandura, J.; Gerds, A. T.; Ritchie, E. K.; Wang, X. L.; Kye, S.; Rampal, R.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib in the United States
    Meeting Abstract

    Marrone, M.; Geller, R.; Oladapo, A.; Suthar, P.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Rampal, R.; Mascarenhas, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma
    Meeting Abstract

    Falchi, L.; Walker, P.; Presgrave, P.; Gregory, G. P.; Marie, D.; Leyco, A. J.; Demaria, O.; Le Floch, F.; Hanekom, W.; Bonin, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma
    Meeting Abstract

    Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Shaverdian, N.; Ricciuti, B.; Alessi, J. V. M.; De Giglio, A.; Pecci, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save